MDXH חוב כולל להון MDxHealth

This price chart for MDxHealth SA (MDXH) reflects a metric of 0.00. MDxHealth SA (MDXH) develops unique molecular tests for prostate cancer detection, and the recognition of these tests by insurers enables the implementation of premium pricing. The high precision of genomic markers renders demand inelastic. A steady influx of funds is secured by urologist loyalty, transforming the technology into a reliable cash cow with a sustainable operating cash flow.

This ratio is calculated as total liabilities divided by equity, reflecting the capital structure's dependence on borrowed resources. This metric determines the degree of financial risk and the company's resilience to external shocks. For molecular diagnostics leader MDxHealth (MDXH), the debt balance is critical when scaling unique, high-precision tests. By analyzing the financial leverage ratio (total debt to equity), an investor assesses the efficiency of capital management.